Several mainstream media outlets are reporting that the U.S. Department of Health and Human Services has removed a requirement mandating that all investigative protocols seeking cannabis for clinical study must undergo a Public Health Service review. The review process, which was enacted in 1999 and applied only to clinical studies involving cannabis, was long criticized by advocates as unnecessarily burdensome and time-consuming.
Commenting on the change, a Health and Human Services spokeswoman said, “The department expects the action announced today will help facilitate further research to advance our understanding about the health risks and any potential benefits of medications using marijuana or its components or derivatives.”
But as I pointed out in today’s news wire coverage, such claims are likely overstated.
That is because unique hurdles to clinical cannabis research will continue to exist as long as the plant is a) classified as a Schedule I controlled substance defined as possessing no medical use and b) the source material for clinical trials must be provided by the U.S. government’s lone supplier, the University of Mississippi (which is overseen by the U.S. National Institute on Drug Abuse).
Further, despite this announced change, the DEA and NIDA (along with the FDA) still must oversee all clinical marijuana research. One of these agencies (the DEA) is in place to enforce the federal criminal prohibition of marijuana. The other agency (NIDA) exists largely as an outgrowth of marijuana’s Schedule I status. It remains highly unlikely that the very agencies in place to oversee and preserve cannabis prohibition would ever permit the type of rational review that would ultimately lead policymakers and the public to question the status quo.
Finally, it bears repeating that ample scientific research already exists to contradict cannabis’ Schedule I status as a substance without medical utility, lacking acceptable safety, and possessing a high potential of abuse. More clinical research is welcome, but unfortunately science has never driven marijuana policy. If it did, the United States would already have a very different policy in place.
The hemp clothing industry is making a resurgence as a popular textile choice.
It’s time to take a stand against gas station weed.
Connecticut lawmakers have passed legislation to regulate hemp products, including a provision that sets a…
Medical cannabis patients who were administered high-THC marijuana flower found the experience to be both…
An Australian biopharma company said Thursday that it has received approval to begin a series…
Ohio's recreational market remains in limbo, for now.